Symbols / SAVA $2.38 +12.26% Cassava Sciences Inc
SAVA Chart
About
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
Fundamentals
Scroll to Statements| Market Cap | 114.97M | Enterprise Value | -5.12M | Income | -106.03M | Sales | — | Book/sh | 1.69 | Cash/sh | 2.20 |
| Dividend Yield | — | Payout | 0.00% | Employees | 30 | IPO | Jul 14, 2000 | P/E | — | Forward P/E | -1.34 |
| PEG | — | P/S | — | P/B | 1.41 | P/C | — | EV/EBITDA | 0.07 | EV/Sales | — |
| Quick Ratio | 2.23 | Current Ratio | 2.27 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | -2.22 | EPS next Y | -1.77 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-05-07 | ROA | -24.80% | ROE | -85.44% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 48.31M | Shs Float | 42.98M | Short Float | 14.89% |
| Short Ratio | 9.40 | Short Interest | — | 52W High | 4.98 | 52W Low | 1.15 | Beta | -0.84 | Avg Volume | 777.18K |
| Volume | 2.06M | Target Price | $8.00 | Recom | None | Prev Close | $2.12 | Price | $2.38 | Change | 12.26% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.00
Mean price target
2. Current target
$2.38
Latest analyst target
3. DCF / Fair value
$6.92
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.38
Low
$8.00
High
$8.00
Mean
$8.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-10-06 | init | LUCID CAPITAL MARKETS | — → Buy | $8 |
| 2025-03-25 | reit | HC Wainwright & Co. | Neutral → Neutral | $2 |
| 2025-03-04 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-11-26 | down | HC Wainwright & Co. | Buy → Neutral | $116 |
| 2024-11-08 | reit | HC Wainwright & Co. | Buy → Buy | $116 |
| 2024-10-08 | up | HC Wainwright & Co. | Neutral → Buy | $116 |
| 2024-08-13 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-08-08 | reit | Rodman & Renshaw | Buy → Buy | $107 |
| 2024-07-19 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-07-01 | down | Jones Trading | Buy → Hold | — |
| 2024-07-01 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2024-05-17 | main | HC Wainwright & Co. | Buy → Buy | $131 |
| 2024-03-05 | reit | HC Wainwright & Co. | Buy → Buy | $124 |
| 2023-08-08 | reit | HC Wainwright & Co. | Buy → Buy | $124 |
| 2023-07-06 | reit | HC Wainwright & Co. | Buy → Buy | $124 |
| 2023-05-11 | reit | HC Wainwright & Co. | Buy → Buy | $124 |
| 2023-05-09 | reit | HC Wainwright & Co. | — → Buy | $124 |
| 2023-03-06 | reit | HC Wainwright & Co. | — → Buy | $124 |
| 2023-01-24 | reit | HC Wainwright & Co. | — → Buy | $124 |
| 2022-08-11 | main | B. Riley Securities | — → Buy | $44 |
- $SAVA stock is up 13% today. Here's what we see in our data. - Quiver Quantitative ue, 24 Feb 2026 08
- Cassava Sciences (NASDAQ:SAVA) Stock Price Up 1.8% - Here's What Happened - MarketBeat hu, 02 Apr 2026 07
- Cassava Sciences (SAVA): Evaluating Valuation After CEO’s Major Share Purchase and Alzheimer’s Program Withdrawal - Yahoo Finance Sat, 27 Sep 2025 07
- Alzheimer’s drug trial data reveal blood test limits and safety clues - Stock Titan ue, 13 Jan 2026 08
- FLNA Stock Price and Chart — NASDAQ:FLNA - TradingView Wed, 11 Mar 2026 18
- Cassava Sciences stock rises after DOJ closes investigation By Investing.com - Investing.com hu, 19 Feb 2026 08
- Cassava Sciences spikes as CEO buys stock - MSN Fri, 21 Nov 2025 13
- Biggest stock movers Tuesday: SAVA, CLSK, PLUG, and more - Seeking Alpha ue, 23 Sep 2025 07
- Cassava Sciences Stock On Track For Worst Day In About 9 Months — What’s Driving Today’s Selloff? - Stocktwits Fri, 19 Dec 2025 08
- $SAVA stock is up 11% today. Here's what we see in our data. - Quiver Quantitative Wed, 26 Nov 2025 08
- Biotech Cassava will pay $31.25M to end investor lawsuit from 2021 - Stock Titan ue, 23 Dec 2025 08
- Cassava Boss Buys Big As Stock Collapses - Yahoo Finance ue, 23 Sep 2025 07
- Cassava Sciences stock falls after FDA places clinical trial on hold - Investing.com Fri, 19 Dec 2025 08
- Cassava Sciences (NASDAQ: SAVA) holds $106.1M cash; expected to support operations into 2027 - Stock Titan Wed, 12 Nov 2025 08
- $SAVA stock is up 26% today. Here's what we see in our data. - Quiver Quantitative ue, 23 Sep 2025 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
96.13
-32.44%
|
142.28
+32.56%
|
107.33
+31.73%
|
81.48
|
| Research And Development |
|
26.59
-61.82%
|
69.64
-22.13%
|
89.42
+31.44%
|
68.03
|
| Selling General And Administration |
|
68.80
-4.19%
|
71.81
+334.31%
|
16.53
+37.92%
|
11.99
|
| General And Administrative Expense |
|
68.80
-4.19%
|
71.81
+334.31%
|
16.53
+37.92%
|
11.99
|
| Other Gand A |
|
68.80
-4.19%
|
71.81
+334.31%
|
16.53
+37.92%
|
11.99
|
| Other Operating Expenses |
|
0.74
-11.64%
|
0.83
-39.46%
|
1.38
-5.88%
|
1.46
|
| Total Expenses |
|
96.13
-32.44%
|
142.28
+32.56%
|
107.33
+31.73%
|
81.48
|
| Operating Income |
|
-96.13
+32.44%
|
-142.28
-32.56%
|
-107.33
-31.73%
|
-81.48
|
| Total Operating Income As Reported |
|
-95.39
+32.56%
|
-141.45
-33.49%
|
-105.96
-32.41%
|
-80.02
|
| EBITDA |
|
-95.19
+32.56%
|
-141.15
-33.41%
|
-105.80
-31.96%
|
-80.18
|
| Normalized EBITDA |
|
-95.19
+61.82%
|
-249.33
-135.65%
|
-105.80
-31.96%
|
-80.18
|
| Reconciled Depreciation |
|
0.94
-17.31%
|
1.13
-26.01%
|
1.53
+17.60%
|
1.30
|
| EBIT |
|
-96.13
+32.44%
|
-142.28
-32.56%
|
-107.33
-31.73%
|
-81.48
|
| Total Unusual Items |
|
—
|
108.18
|
—
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
—
|
108.18
|
—
|
0.00
|
| Special Income Charges |
|
—
|
—
|
—
|
0.00
|
| Net Income |
|
-90.97
-273.73%
|
-24.34
+74.96%
|
-97.22
-27.50%
|
-76.25
|
| Pretax Income |
|
-90.97
-273.73%
|
-24.34
+74.96%
|
-97.22
-27.50%
|
-76.25
|
| Net Non Operating Interest Income Expense |
|
4.62
-45.71%
|
8.51
+8.64%
|
7.83
+182.07%
|
2.78
|
| Net Interest Income |
|
4.62
-45.71%
|
8.51
+8.64%
|
7.83
+182.07%
|
2.78
|
| Interest Income Non Operating |
|
4.62
-45.71%
|
8.51
+8.64%
|
7.83
+182.07%
|
2.78
|
| Interest Income |
|
4.62
-45.71%
|
8.51
+8.64%
|
7.83
+182.07%
|
2.78
|
| Other Income Expense |
|
0.53
-99.51%
|
109.43
+4693.12%
|
2.28
-7.16%
|
2.46
|
| Other Non Operating Income Expenses |
|
0.53
-57.15%
|
1.24
-45.51%
|
2.28
-7.16%
|
2.46
|
| Gain On Sale Of Security |
|
—
|
108.18
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-90.97
-273.73%
|
-24.34
+74.96%
|
-97.22
-27.50%
|
-76.25
|
| Net Income From Continuing Operation Net Minority Interest |
|
-90.97
-273.73%
|
-24.34
+74.96%
|
-97.22
-27.50%
|
-76.25
|
| Net Income From Continuing And Discontinued Operation |
|
-90.97
-273.73%
|
-24.34
+74.96%
|
-97.22
-27.50%
|
-76.25
|
| Net Income Continuous Operations |
|
-90.97
-273.73%
|
-24.34
+74.96%
|
-97.22
-27.50%
|
-76.25
|
| Normalized Income |
|
-90.97
+31.35%
|
-132.53
-36.32%
|
-97.22
-27.50%
|
-76.25
|
| Net Income Common Stockholders |
|
-90.97
-273.73%
|
-24.34
+74.96%
|
-97.22
-27.50%
|
-76.25
|
| Diluted EPS |
|
-1.88
-28.77%
|
-1.46
+37.07%
|
-2.32
-22.11%
|
-1.90
|
| Basic EPS |
|
-1.88
-254.72%
|
-0.53
+77.16%
|
-2.32
-22.11%
|
-1.90
|
| Basic Average Shares |
|
48.30
+4.25%
|
46.33
+10.49%
|
41.93
+4.30%
|
40.20
|
| Diluted Average Shares |
|
48.30
+3.63%
|
46.60
+11.14%
|
41.93
+4.30%
|
40.20
|
| Diluted NI Availto Com Stockholders |
|
-90.97
-33.52%
|
-68.14
+29.91%
|
-97.22
-27.50%
|
-76.25
|
| Average Dilution Earnings |
|
0.00
+100.00%
|
-43.79
|
0.00
|
0.00
|
| Gain On Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
118.36
-24.87%
|
157.53
+3.87%
|
151.66
-35.42%
|
234.83
|
| Current Assets |
|
97.71
-28.44%
|
136.53
+5.32%
|
129.63
-38.63%
|
211.23
|
| Cash Cash Equivalents And Short Term Investments |
|
95.50
-25.72%
|
128.57
+6.14%
|
121.14
-39.74%
|
201.01
|
| Cash And Cash Equivalents |
|
95.50
-25.72%
|
128.57
+6.14%
|
121.14
-39.74%
|
201.01
|
| Receivables |
|
0.12
-87.33%
|
0.95
-1.56%
|
0.96
|
0.00
|
| Accrued Interest Receivable |
|
0.12
-87.33%
|
0.95
-1.56%
|
0.96
|
0.00
|
| Prepaid Assets |
|
2.02
-70.99%
|
6.97
-3.79%
|
7.25
-27.89%
|
10.05
|
| Other Current Assets |
|
0.06
+68.42%
|
0.04
-86.76%
|
0.29
+79.38%
|
0.16
|
| Total Non Current Assets |
|
20.65
-1.69%
|
21.00
-4.67%
|
22.03
-6.68%
|
23.61
|
| Net PPE |
|
20.65
-1.69%
|
21.00
-3.90%
|
21.85
-4.92%
|
22.99
|
| Gross PPE |
|
24.79
+2.26%
|
24.24
+0.41%
|
24.14
-0.20%
|
24.19
|
| Accumulated Depreciation |
|
-4.14
-27.90%
|
-3.24
-41.68%
|
-2.28
-90.33%
|
-1.20
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Land And Improvements |
|
3.73
+0.00%
|
3.73
+0.00%
|
3.73
+0.00%
|
3.73
|
| Buildings And Improvements |
|
15.98
+0.00%
|
15.98
+0.00%
|
15.98
-0.76%
|
16.10
|
| Machinery Furniture Equipment |
|
0.89
+1.83%
|
0.88
+0.81%
|
0.87
+2.00%
|
0.85
|
| Construction In Progress |
|
0.03
-54.55%
|
0.06
|
0.00
-100.00%
|
0.01
|
| Other Properties |
|
0.69
+29.38%
|
0.53
+7.49%
|
0.49
+5.11%
|
0.47
|
| Leases |
|
3.47
+13.26%
|
3.06
+0.00%
|
3.06
+1.53%
|
3.02
|
| Goodwill And Other Intangible Assets |
|
—
|
0.04
-78.98%
|
0.18
-71.70%
|
0.62
|
| Other Intangible Assets |
|
—
|
0.04
-78.98%
|
0.18
-71.70%
|
0.62
|
| Other Non Current Assets |
|
—
|
—
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
43.95
+271.56%
|
11.83
-16.67%
|
14.20
+94.59%
|
7.29
|
| Current Liabilities |
|
43.83
+273.06%
|
11.75
-17.22%
|
14.20
+100.98%
|
7.06
|
| Payables And Accrued Expenses |
|
42.01
+316.20%
|
10.09
-25.83%
|
13.61
+116.13%
|
6.30
|
| Payables |
|
41.65
+444.12%
|
7.65
-27.61%
|
10.57
+163.21%
|
4.02
|
| Accounts Payable |
|
41.65
+444.12%
|
7.65
-27.61%
|
10.57
+163.21%
|
4.02
|
| Current Accrued Expenses |
|
0.36
-85.08%
|
2.44
-19.66%
|
3.04
+33.20%
|
2.28
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
1.62
+19.75%
|
1.36
+578.50%
|
0.20
+17.65%
|
0.17
|
| Current Debt And Capital Lease Obligation |
|
—
|
—
|
—
|
0.10
|
| Current Capital Lease Obligation |
|
—
|
—
|
0.00
-100.00%
|
0.10
|
| Other Current Liabilities |
|
0.20
-33.78%
|
0.30
-22.34%
|
0.39
-21.75%
|
0.49
|
| Total Non Current Liabilities Net Minority Interest |
|
0.12
+49.37%
|
0.08
|
0.00
-100.00%
|
0.23
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
—
|
0.00
-100.00%
|
0.04
|
| Long Term Capital Lease Obligation |
|
—
|
—
|
0.00
-100.00%
|
0.04
|
| Other Non Current Liabilities |
|
0.12
+49.37%
|
0.08
|
—
|
0.20
|
| Stockholders Equity |
|
74.40
-48.94%
|
145.70
+5.99%
|
137.47
-39.58%
|
227.54
|
| Common Stock Equity |
|
74.40
-48.94%
|
145.70
+5.99%
|
137.47
-39.58%
|
227.54
|
| Capital Stock |
|
0.05
+0.00%
|
0.05
+14.29%
|
0.04
+0.00%
|
0.04
|
| Common Stock |
|
0.05
+0.00%
|
0.05
+14.29%
|
0.04
+0.00%
|
0.04
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
48.31
+0.22%
|
48.20
+14.13%
|
42.24
+1.20%
|
41.74
|
| Ordinary Shares Number |
|
48.31
+0.22%
|
48.20
+14.13%
|
42.24
+1.20%
|
41.74
|
| Additional Paid In Capital |
|
570.44
+3.57%
|
550.77
+6.29%
|
518.20
+1.40%
|
511.05
|
| Retained Earnings |
|
-496.08
-22.46%
|
-405.11
-6.39%
|
-380.77
-34.29%
|
-283.55
|
| Total Equity Gross Minority Interest |
|
74.40
-48.94%
|
145.70
+5.99%
|
137.47
-39.58%
|
227.54
|
| Total Capitalization |
|
74.40
-48.94%
|
145.70
+5.99%
|
137.47
-39.58%
|
227.54
|
| Working Capital |
|
53.88
-56.82%
|
124.78
+8.09%
|
115.44
-43.46%
|
204.16
|
| Invested Capital |
|
74.40
-48.94%
|
145.70
+5.99%
|
137.47
-39.58%
|
227.54
|
| Total Debt |
|
—
|
—
|
0.00
-100.00%
|
0.14
|
| Capital Lease Obligations |
|
—
|
—
|
0.00
-100.00%
|
0.14
|
| Net Tangible Assets |
|
74.40
-48.94%
|
145.70
+6.13%
|
137.29
-39.50%
|
226.92
|
| Tangible Book Value |
|
74.40
-48.94%
|
145.70
+6.13%
|
137.29
-39.50%
|
226.92
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-32.25
+72.42%
|
-116.93
-42.55%
|
-82.03
-5.82%
|
-77.51
|
| Cash Flow From Continuing Operating Activities |
|
-32.25
+72.42%
|
-116.93
-42.55%
|
-82.03
-5.82%
|
-77.51
|
| Net Income From Continuing Operations |
|
-90.97
-273.73%
|
-24.34
+74.96%
|
-97.22
-27.50%
|
-76.25
|
| Depreciation Amortization Depletion |
|
0.94
-17.31%
|
1.13
-26.01%
|
1.53
+17.60%
|
1.30
|
| Depreciation |
|
0.90
-5.15%
|
0.95
-12.18%
|
1.08
+34.83%
|
0.80
|
| Amortization Cash Flow |
|
0.03
-81.67%
|
0.18
-59.64%
|
0.45
-10.26%
|
0.50
|
| Depreciation And Amortization |
|
0.94
-17.31%
|
1.13
-26.01%
|
1.53
+17.60%
|
1.30
|
| Amortization Of Intangibles |
|
0.03
-81.67%
|
0.18
-59.64%
|
0.45
-10.26%
|
0.50
|
| Stock Based Compensation |
|
19.58
+20.20%
|
16.29
+255.23%
|
4.59
+121.97%
|
2.07
|
| Operating Gains Losses |
|
—
|
-108.18
|
—
|
—
|
| Gain Loss On Investment Securities |
|
—
|
-108.18
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Change In Working Capital |
|
38.20
+2191.02%
|
-1.83
-120.13%
|
9.08
+295.81%
|
-4.63
|
| Change In Prepaid Assets |
|
6.08
+1028.01%
|
0.54
-68.55%
|
1.71
+44.15%
|
1.19
|
| Change In Payables And Accrued Expense |
|
31.92
+1007.76%
|
-3.52
-145.94%
|
7.65
+292.67%
|
-3.97
|
| Change In Accrued Expense |
|
-2.08
-247.74%
|
-0.60
-178.86%
|
0.76
+244.74%
|
-0.52
|
| Change In Payable |
|
33.99
+1264.54%
|
-2.92
-142.33%
|
6.90
+299.94%
|
-3.45
|
| Change In Account Payable |
|
33.99
+1264.54%
|
-2.92
-142.33%
|
6.90
+299.94%
|
-3.45
|
| Change In Other Working Capital |
|
0.27
-76.84%
|
1.16
+8800.00%
|
0.01
+100.76%
|
-1.72
|
| Change In Other Current Liabilities |
|
-0.06
-785.71%
|
-0.01
+97.70%
|
-0.30
-123.53%
|
-0.14
|
| Investing Cash Flow |
|
-0.58
-464.08%
|
-0.10
+75.12%
|
-0.41
+84.73%
|
-2.71
|
| Cash Flow From Continuing Investing Activities |
|
-0.58
-464.08%
|
-0.10
+75.12%
|
-0.41
+84.73%
|
-2.71
|
| Net PPE Purchase And Sale |
|
-0.58
-464.08%
|
-0.10
+75.12%
|
-0.41
+84.73%
|
-2.71
|
| Purchase Of PPE |
|
-0.58
-464.08%
|
-0.10
+75.12%
|
-0.41
+84.73%
|
-2.71
|
| Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Capital Expenditure |
|
-0.58
-464.08%
|
-0.10
+75.12%
|
-0.41
+84.73%
|
-2.71
|
| Financing Cash Flow |
|
-0.24
-100.19%
|
124.47
+4762.11%
|
2.56
-94.64%
|
47.80
|
| Cash Flow From Continuing Financing Activities |
|
-0.24
-100.19%
|
124.47
+4762.11%
|
2.56
-94.64%
|
47.80
|
| Net Common Stock Issuance |
|
—
|
0.00
|
0.00
-100.00%
|
47.33
|
| Proceeds From Stock Option Exercised |
|
0.09
-99.93%
|
124.47
+4762.11%
|
2.56
+438.95%
|
0.47
|
| Net Other Financing Charges |
|
-0.33
|
—
|
—
|
—
|
| Changes In Cash |
|
-33.07
-544.64%
|
7.44
+109.31%
|
-79.88
-146.37%
|
-32.42
|
| Beginning Cash Position |
|
128.57
+6.14%
|
121.14
-39.74%
|
201.01
-13.89%
|
233.44
|
| End Cash Position |
|
95.50
-25.72%
|
128.57
+6.14%
|
121.14
-39.74%
|
201.01
|
| Free Cash Flow |
|
-32.83
+71.95%
|
-117.03
-41.96%
|
-82.44
-2.76%
|
-80.23
|
| Common Stock Issuance |
|
—
|
0.00
|
0.00
-100.00%
|
47.33
|
| Issuance Of Capital Stock |
|
—
|
0.00
|
0.00
-100.00%
|
47.33
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|